硼替佐米对多发性骨髓瘤患者T淋巴细胞、血栓发生风险及预后的影响
Effects of bortezomib on T lymphocytes,incidence risk of thrombus,and prognosis in patients with multiple my-eloma
罗信国 1叶虹位 1胡姗姗 1许维东2
作者信息
- 1. 321000 浙江金华,金华市人民医院血液科
- 2. 321000 浙江金华,金华市人民医院检验科
- 折叠
摘要
目的 探讨硼替佐米对多发性骨髓瘤患者T淋巴细胞、血栓发生风险及预后的影响.方法 回顾性选择150 例多发性骨髓瘤患者,分为观察组和对照组,各75 例.观察组采用含硼替佐米的化疗方案进行干预,对照组采用常规化疗治疗方式进行干预,均干预6 个疗程.分别于治疗前与治疗后比较两组的血清CD3+、CD4+、CD4+/CD8+、Treg、肿瘤坏死因子-α(TNF-α)、白细胞介素-1β(IL-1β)水平,记录两组患者化疗期间血栓的发生情况,评估临床疗效和预后生存情况.结果 治疗后,观察组患者的TNF-α、IL-1β明显低于对照组,差异均有统计学意义(t分别=4.63、9.52,P均＜0.05),CD3+、CD4+、CD4+/CD8+、Treg均明显高于对照组,差异均有统计学意义(t分别=4.63、9.52、6.21、2.65,P均＜0.05).治疗后,观察组患者的血栓发生率明显低于对照组,临床治疗有效率明显高于对照组,差异有统计学意义(χ2分别=5.04、13.53,P均＜0.05).随访2年内,观察组生存率为96.00%,对照组为92.00%,两组患者的生存率比较,差异无统计学意义(χ2=1.06,P＞0.05).结论 硼替佐米在多发性骨髓瘤的治疗中改善患者T淋巴细胞表达水平、降低炎症水平及血栓的发生风险,对于提高患者治疗效果有积极作用.
Abstract
Objective To investigate the effects of bortezomib on T lymphocytes,incidence risk of thrombus and prog-nosis in patients with multiple myeloma.Methods Totally 150 patients with multiple myeloma were selected and divid-ed into observation group and control group,75 cases each.The observation group was treated with bortezomib chemother-apy,while the control group was treated with conventional chemotherapy for 6 courses of intervention.Serum levels of CD3+,CD4+,CD4+/CD8+,Treg,tumor necrosis factor-α(TNF-α)and interleukin-1β(IL-1β)were compared between the two groups before and after treatment,and the incideice of thrombus during chemotherapy was recorded in the two groups,and the clinical efficacy and prognosis were evaluated.Results After treatment,TNF-α and IL-1β in observa-tion group were significantly lower than those in control group,the differences were statistically significant(t=4.63,9.52,P＜0.05),and CD3+,CD4+,CD4+/CD8+ and Treg were significantly higher than those in control group(t=4.63,9.52,6.21,2.65,P＜0.05).After treatment,the incidence of thrombus in observation group was significantly lower than that in con-trol group,and clinical efficiency was significantly higher than that in control group,with statistical significance(χ2= 5.04,13.53,P＜0.05).Within 2 years of follow-up,the survival rate of the observation group was 96.00%and that of the control group was 92.00%.There was no statistical significance in the survival rate between the two groups(χ2=1.06,P＞0.05).Conclusion In the treatment of multiple myeloma,bortezomib can improve the expression level of T lympho-cytes,reduce the level of inflammation and the risk of thrombus,and play a positive role in improving the treatment ef-fect of patients.
关键词
硼替佐米/多发性骨髓瘤/T淋巴细胞/血栓/预后Key words
bortezomib/multiple myeloma/T lymphocytes/thrombus/prognosis引用本文复制引用
基金项目
金华市科学技术研究计划(2021-4-075)
出版年
2024
NETL
NSTL
万方数据